# **Special Issue**

# Clinical and Translational Research in Gastrointestinal Cancers (2nd Edition)

### Message from the Guest Editors

Gastrointestinal (GI) cancers pose a major challenge to global public health. In 2018, Arnold and colleagues (PMID: 32247694) estimated that there were 4.8 million new cases of GI cancers and 3.4 million related deaths worldwide. Lu and colleagues (PMID: 34563100) have recently quantified the involvement of lifestyle-related factors in the development of GI cancers. There remain many options for the primary and secondary prevention of these cancers, and their management is also evolving. Minimally invasive (laparoscopic and robotic) surgery is increasingly applied to complement open surgery. Chemotherapy and radiation therapy have not extended the duration of disease-free survival, but have also had a significant impact on overall survival. The last decade has witnessed a paradigm shift, with a growing interest in cancer survivorship and quality of life. This Special Issue aims to bring together original research and impactful reviews from around the world that highlight developments in the management of a broad spectrum of GI cancers, including survivorship.

#### **Guest Editors**

Dr. Savio Barreto

HPB Unit, Flinders Medical Centre & Flinders University, Adelaide 5001, Australia

Prof. Dr. Jörg Kleeff

Department of Visceral, Vascular and Endocrine Surgery, University Hospital Halle (Saale), Ernst-Grube-Str. 40, 06120 Halle, Germany

### Deadline for manuscript submissions

closed (31 August 2025)



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/223999

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com\_

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

